At its July meeting, the Pharmaceutical Benefits Advisory Committee disappointed stakeholders with outcomes on RSV vaccines and contraceptives but appears to have relented on a risk-sharing arrangement in response to a company's delisting request. …
July outcomes disappoint but committee appears to relent on risk share arrangement
August 26, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
Georgia Forrest
New Stories
-
Setting the standard for safe and accountable virtual healthcare in Australia
March 4, 2026 - - Latest News -
A system built for a past is struggling to meet the challenge of today, let alone the future
March 4, 2026 - - Latest News -
Firebrick Pharma targets breakout year in 2026 as Nasodine expansion accelerates
March 4, 2026 - - Australian Biotech -
AdAlta strengthens clinical push for breakthrough solid cancer therapy
March 4, 2026 - - Australian Biotech -
Island Pharmaceuticals deepens US biodefence ties to advance Marburg treatment
March 4, 2026 - -
PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise
March 4, 2026 - - Australian Biotech -
Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen
March 4, 2026 - - Australian Biotech